- News & Features
A new type of biologics called JAK inhibitors are so new that many clinicians don’t know about them.
“There is a long history of bias in healthcare in the United States against LGBT people and there are also significant healthcare disparities in these populations.”
The phrase “clear as mud” came up several times in the introduction Dr. William Harvey delivered at the 2016 ACR Annual Meeting about the Medicare Access and CHIP Reauthorization Act of 2015.
There are a variety of “integrative” medical approaches that can also be beneficial to patients, says Dr. Randy Horwitz.
Biosimilars carry about a 20 to 30 percent reduction in cost over the biologics that they resemble, says Dr. Candida Fratazzi.
Two new studies provide "rationale for further investigation into the usefulness of happiness as a tool to inform treatment decision making in ankylosing spondylitis and psoriatic arthritis,” researchers said.
The study relied on a “really carefully thought out” enzyme-linked immunosorbent assay (ELISA) test to detect drug levels in breast milk.
“The field of spondyloarthritis treatment is going through the same excitement and expansion that rheumatoid arthritis treatment went through 10 years ago,” said Dr. Atul Deodhar.
Rheumatologists and orthopedists created new guidelines with recommendations for the perioperative management of anti-rheumatic therapy.
For Dr. Victor Paquet, a "smart" home should adapt to individual users, including those with rheumatic disease.
The talk was titled “Delivering Care for Rheumatic Patients in the 21st Century.”